Chemical formula: C₁₀H₁₄N₂O₂ Molecular mass: 194.234 g/mol
Solriamfetol is indicated to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Its mechanism of action has not been fully characterised. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine (noradrenaline) reuptake inhibitor (DNRI).
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06BA14 | N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SUNOSI Film‑coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Solriamfetol is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Israel (IL)
Italy (IT)
Lithuania (LT)
Poland (PL)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
